Evidence map›Paper›PMID 41915173›Full record

Trial reportIntensive care medicine2026

Short-term light sedation with remimazolam besylate versus propofol in the ICU (SHOSREB): a multicentre, randomized, single-blind, controlled trial.

Xiaobo Yang, Jingye Pan, Xun Gong, Ailian Lv, Fengming Liang, Jing Liu, Dezhong Li, Shouzhi Fu, Aijun Pan, Li Yu and 18 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter StudyComparative Study
PubMed Publisher
In one paragraph

Trial report in Intensive care medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05782894 (A Multicenter, Randomized, Single-blinded, Parallel, Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Injection for Sedation in ICU Patients), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05782894 phase3completednot on this map

A Multicenter, Randomized, Single-blinded, Parallel, Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Injection for Sedation in ICU Patients

TypeinterventionalSponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyRan2023 to 2023Enrolled164ConditionsSedative, Mechanical VentilationArmsRemimazolam besylate, Propofol, Remifentanil
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Xiaobo Yang *Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China. want.tofly@aliyun.com.
Jingye Pan *Department of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.
Xun Gong *Department of Critical Care Medicine, Yichang Central People's Hospital, Yichang, Hubei Province, China.
Ailian Lv *Department of Critical Care Medicine, The First Hospital of Changsha, Changsha, Hunan Province, China.
Fengming Liang *Department of Critical Care Medicine, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu Province, China.
Jing Liu *Department of Critical Care Medicine, Chongqing University Jiangjin Hospital, Chongqing, China.
Dezhong LiDepartment of Critical Care Medicine, The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Enshi, Hubei Province, China.
Shouzhi FuDepartment of Critical Care Medicine, Wuhan Third Hospital Province, Wuhan, Hubei Province, China.
Aijun PanDepartment of Critical Care Medicine, Anhui Provincial Hospital, Hefei, Anhui Province, China.
Li YuDepartment of Critical Care Medicine, The Central Hospital of Wuhan, Wuhan, Hubei Province, China.
Lina ZhangDepartment of Critical Care Medicine, Xiangya Hospital of Central South University, Changsha, Hunan Province, China.
Tao ChenDepartment of Critical Care Medicine, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province, China.
Liying ZhanDepartment of Critical Care Medicine, People's Hospital of Hubei Province, Wuhan, Hubei Province, China.
Bingyu QinDepartment of Critical Care Medicine, Henan Provincial People's Hospital, Zhengzhou, Henan Province, China.
Fenghui LinDepartment of Critical Care Medicine, Provincial Hospital Affiliated to Fuzhou University, Fuzhou, Fujian Province, China.
Xuming XiongDepartment of Critical Care Medicine, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province, China.
Ying ZhuDepartment of Critical Care Medicine, Hangzhou First People's Hospital, Hangzhou, Zhejiang Province, China.
Zhihui HeDepartment of Critical Care Medicine, The Third Xiangya Hospital of Central South University, Changsha, Hunan Province, China.
Renhua SunDepartment of Critical Care Medicine, People's Hospital of Zhejiang, Hangzhou, Zhejiang Province, China.
Tongwen SunDepartment of Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Songzan QianDepartment of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.
Deliang WenDepartment of Critical Care Medicine, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province, China.
Xiaojing ZouDepartment of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
Hong QiDepartment of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
Huaqing ShuDepartment of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
Liping SongYichang Humanwell Pharmaceutical Co. Ltd, Yichang, Hubei Province, China.
Chunhua WangYichang Humanwell Pharmaceutical Co. Ltd, Yichang, Hubei Province, China.
You ShangDepartment of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China. you_shanghust@163.com.ORCID http://orcid.org/0000-0003-4097-6131

Funding

Key Clinical Research Initiative Program of Union Hospital 2025LCYJ06
6 · The paper itself

Abstract

purposeTo explore the efficacy and safety of remimazolam besylate in short-term sedation in the ICU in comparison with propofol.

methodA multicenter, randomized, single-blind, non-inferiority trial was conducted in mechanically ventilated patients, who needed light sedation, defined as Richmond Agitation-Sedation Scale (RASS) scores between -2 and + 1. The primary outcome was successful sedation, which was defined as no rescue sedative administered during the study drug infusion period while maintaining RASS scores between -2 and + 1 for at least 70% of the total infusion time.

resultsA total of 164 participants were included and randomized equally into the remimazolam group and the propofol group. Remimazolam was continuously infused for 10.5 [8.1-14.7] h and propofol for 11.0 [7.0-14.3] h (p = 0.534). The median average maintaining dose of remimazolam and propofol was 0.20 [0.19-0.30] mg·kg⁻

conclusionRemimazolam besylate could be non-inferior to propofol for achieving successful short-term light sedation in the ICU.

trial registrationClinicalTrials.gov identifier: NCT05782894 on Feb 18th, 2023.

Indexed as

BenzodiazepinesHypnotics and SedativesProcedural SedationPropofolAgedFemaleHumansIntensive Care UnitsMaleMiddle AgedRespiration, ArtificialSingle-Blind MethodBenzodiazepinesHypnotics and SedativesPropofolremimazolamIntensive care unitLight sedationPropofolRemimazolamRichmond Agitation–Sedation Scale

Identifiers

PMID41915173

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.